The top-selling product of a leading pharmaceutical group with the indication multiple sclerosis is being extensively investigated in studies. In particular, the pivotal phase III studies are continued as long-term follow-up surveys. The company regularly communicates the results at annual congresses, for example at the European Committees for Treatment and Research in Multiple Sclerosis, the American Academy of Neurology and the German Neurological Society.
Task
The speaker slide decks for speakers and opinion leaders were to be updated based on current congress data.
Implementation/Results
Four slide decks on the topics of ‘B-cell depletion’, “Safety”, ‘Relapsing Multiple Sclerosis’ and ‘Primary Progressive Multiple Sclerosis’ were updated with the data presented at 6 international Multiple Sclerosis congresses in 2021 – 2023. A total of 96 slides were redesigned and over 100 slides were updated with new data, especially for reports on long-term and follow-up studies.
The project was carried out as external support in the area of medical direction/communication.
